Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2020; 8(22): 5576-5588
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5576
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5576
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
Jiang-Hua Zhou, Bin Wu, Wen-Xin Wang, Xu Cheng, Juan-Juan Qin, Ye-Mao Liu, Hao-Miao Li, Department of Cardiology, Renmin Hospital of Wuhan University, Basic Medical School, Wuhan University, Wuhan 430071, Hubei Province, China
Fang Lei, Xiao-Jing Zhang, Basic Medical School, Institute of Model Animal, Wuhan University, Wuhan 430071, Hubei Province, China
Jing-Jing Cai, Department of Cardiology, the 3rd Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China
Feng Zhou, Medical Science Research Center, Zhongnan Hospital of Wuhan University, Institute of Model Animal, Wuhan University, Wuhan 430072, Hubei Province, China
Li-Hua Zhu, Zhi-Gang She, Juan Yang, Hong-Liang Li, Department of Cardiology, Renmin Hospital of Wuhan University; Institute of Model Animal of Wuhan University, Wuhan 430071, Hubei Province, China
Xin Zhang, Institute of Model Animal, Wuhan University, Department of Gastroenterology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430072, Hubei Province, China
Author contributions: Zhou JH, Wu B, and Wang WX contributed equally to the work, designed the study, collected and analyzed the data, and wrote the manuscript; Lei F, Cheng X, Qin JJ, Zhou F, Liu YM, and Li HM performed statistical analysis; Cai JJ, Zhang XJ, Zhu LH, and She ZG wrote the manuscript and provided valuable suggestions for study design and data analysis; Zhang X, Yang J, and Li HL contributed equally to the work, designed the project, edited the manuscript, and supervised the study; all authors have approved the final version of this paper.
Supported by National Key R&D Program of China , No. 2019YFC2004702 and No. 2020YFC0845500 ; the National Natural Science Foundation of China , No. 81970070 and No. 81970011 ; the Hubei Science and Technology Support Project , No. 2019BFC582 and No. 2018BEC473 .
Institutional review board statement: The study was reviewed and approved by the Science and Research Office of Renmin Hospital and Zhongnan Hospital of Wuhan University (Wuhan).
Informed consent statement: Informed consent was waived by the ethics boards of the involved hospitals.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Liang Li, MD, PhD, Professor, Department of Cardiology, Renmin Hospital of Wuhan University; Institute of Model Animal of Wuhan University, No. 115 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. lihl@whu.edu.cn
Received: July 6, 2020
Peer-review started: July 6, 2020
First decision: August 8, 2020
Revised: August 20, 2020
Accepted: September 25, 2020
Article in press: November 26, 2020
Published online: November 26, 2020
Processing time: 141 Days and 23.9 Hours
Peer-review started: July 6, 2020
First decision: August 8, 2020
Revised: August 20, 2020
Accepted: September 25, 2020
Article in press: November 26, 2020
Published online: November 26, 2020
Processing time: 141 Days and 23.9 Hours
Core Tip
Core Tip: Our study illuminated that there were no significant associations between in-hospital use of dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4i) and 28-d all-cause mortality or multiorgan injury. In addition, the glucose control effects, inflammatory response, and associated adverse events were also comparable between patients in the DPP4i and non-DPP4i groups. These data provided direct clinical evidence to support the continuation of DPP4i therapy in diabetic patients with coronavirus disease 2019 (COVID-19). Moreover, this work paves the way for prospective studies and randomized controlled clinical trials on DPP4 inhibitor therapy for COVID-19.